题型:阅读理解 题类:常考题 难易度:普通
云南省玉溪市2020届高三英语第二次教学质量检测试卷
Authorities in China have approved a drug for the treatment of Alzheimer's disease(早老性痴呆), the first new medicine with the potential to treat the cognitive(认知的)disorder in 17 years.
The seaweed-based drug, called Oligomannate, can be used for the treatment of mild to moderate Alzheimer's, according to a statement from China's drug safety agency. The approval is conditional however, meaning that while it can go on sale during additional clinical trials, it will be strictly monitored and could be withdrawn if any safety issues should arise.
In September, the team behind the new drug, led by Geng Meiyu at the Shanghai Institute of Materia Medica under the Chinese Academy of Sciences, said they were inspired to look into seaweed due to the relatively low incidence of Alzheimer's among people who consume it regularly.
In a paper in the journal Cell Research, Geng's team described how a sugar contained within seaweed prevents certain bacteria contained in the gut (肠子) which can cause neural decline and infection of the brain, leading to Alzheimer's.
This mechanism was confirmed during a clinical trial carried out by Green Valley, a Shanghai based pharmaceutical company that will be bringing the new drug to market.
Conducted on 818 patients, the trial found that Oligomannate-which is got from brown algae (海藻)-can statistically improve cognitive function among people with Alzheimer's in as little as four weeks, according to a statement from Green Valley. "
The company said Oligomannate will be available in China" very soon", and it is currently seeking approval to market it abroad, with plans to launch third-phase clinical trials in the US and Europe in early 2020.
试题篮